Sarepta Therapeutics

FDA Lifts Hold on Elevidys Shipments to Ambulatory Duchenne Patients

FDA clearance follows finding that an eight-year-old’s death was unrelated; treatment remains paused for non-ambulatory patients pending safety label updates.